5 recruiting, 3 active not recruiting, 2 completed, 1 available. 6 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Recruiting 2, Active not recruiting 1, Terminated 1 |
| Phase 1 | 4 | Active not recruiting 2, Recruiting 1, Withdrawn 1 |
| Phase 3 | 2 | Recruiting 2 |
Follow lifileucel: new trials by email Literature Review of lifileucel trials Research Report on lifileucel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma Lifileucel - Sarcoma, Soft Tissue Sarcoma (STS) | Phase 2 | Recruiting | Iovance Biotherapeutics, Inc. | 80 | 2026-10-02 | 2026-10-09 |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma Lifileucel - Melanoma (Skin Cancer), Unresectable Melanoma | Phase 2 | Active not recruiting | Iovance Biotherapeutics, Inc. | 24 | 2025-11-28 | 2026-10-01 |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma IMA203, nivolumab plus relatlimab, lifileucel - Melanoma, Cutaneous Malignant | Phase 3 | Recruiting | Immatics US, Inc. | 360 | 2025-01-14 | 2026-08-18 |
| Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma LN-144, Cyclophosphamide, Mesna - Stage IIIB Melanoma, Stage IIIC Melanoma | Phase 1 | Withdrawn | James Isaacs, MD | 2024-12-02 | 2025-06-05 | |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. Lifileucel - Endometrial Cancer | Phase 2 | Recruiting | Iovance Biotherapeutics, Inc. | 60 | 2024-10-29 | 2025-10-30 |
| Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma Biospecimen Collection, Cyclophosphamide, Echocardiography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma | Phase 2 | Completed | University of Kansas Medical Center | 11 | 2023-12-21 | 2026-04-30 |
| Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period - Metastatic Melanoma, Unresectable Melanoma | Phase 3 | Recruiting | Iovance Biotherapeutics, Inc. | 670 | 2023-03-30 | 2026-09-24 |
| A Study of LN-144 in People With Metastatic Melanoma to the Brain Lifileucel (LN-144) - Metastatic Melanoma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 10 | 2022-11-25 | 2026-09-11 |
| A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma Lifileucel (LN-144/LN-145) - Uveal Melanoma, Melanoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2022-11-01 | 2026-09-15 |
| Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients Cyclophosphamide, Fludarabine, Lifileucel - Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Phase 1 | Active not recruiting | Richard Wu | 2 | 2022-07-01 | 2026-02-24 |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors Lifileucel, LN-145, Pembrolizumab - Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Terminated | Iovance Biotherapeutics, Inc. | 225 | 2019-05-07 | 2026-05-15 |
| Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma Lifileucel - Metastatic Melanoma | Phase 2 | Completed | Iovance Biotherapeutics, Inc. | 220 | 2015-09-24 | 2026-03-25 |
| Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release OOS AMTAGVI - Unresectable Melanoma, Metastatic Melanoma | Available | Iovance Biotherapeutics, Inc. | 2026-04-20 |
Melanoma (10) · Skin Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Endometrial Neoplasms (1) · Histiocytoma, Malignant Fibrous (1) · Liposarcoma (1) · Melanoma, Cutaneous Malignant (1) · Sarcoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Uveal Melanoma (1)
Iovance Biotherapeutics, Inc. (7) · Memorial Sloan Kettering Cancer Center (2) · Immatics US, Inc. (1) · James Isaacs, MD (1) · Richard Wu (1) · University of Kansas Medical Center (1)
United States (12) · United Kingdom (5) · Canada (4) · Germany (4) · France (3) · Spain (3) · Switzerland (3) · Australia (2) · Italy (2) · Netherlands (2) · Belgium (1) · Finland (1) · Greece (1) · Hungary (1) · Israel (1)
Alexander Shoushtari, MD (1) · Cedrik Britten, M.D. (1) · James Isaacs, MD (1) · Lauren Banks, MD, PhD (1) · Muhammad Umair Mushtaq (1) · Richard C Wu, M.D. Ph.D. (1)
PMID 33979178, PMID 35880942, PMID 40343719
2018 (1), 2025 (1), P30CA168524 (1)